# Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct06760520/  
OnCo record `nct06760520` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by The First Affiliated Hospital of Zhengzhou University, not yet recruiting.

## Summary

Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT06760520 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 40 participants, started 2025-01-20 and due to reach its primary completion in 2027-12-20. Interventions recorded: Ivonescimab (SMT112 or AK112) Injection. Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: Complete response rate (CR, pCR plus cCR ). Colorectal eligibility wording from the registry: "* histologically or cytologically confirmed colorectal adenocarcinoma with non-distant metastasis". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06760520
- Phase: 2
- Setting: A Single-arm, Prospective, Phase II Clinical Study of Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Low-middle Rectal Cancer with a High Risk of Recurrence
- Sponsor: The First Affiliated Hospital of Zhengzhou University
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06760520: https://clinicaltrials.gov/study/NCT06760520

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06760520.json